227 related articles for article (PubMed ID: 16100339)
41. Mechanisms of Disease: leukotrienes and lipoxins in scleroderma lung disease--insights and potential therapeutic implications.
Kowal-Bielecka O; Kowal K; Distler O; Gay S
Nat Clin Pract Rheumatol; 2007 Jan; 3(1):43-51. PubMed ID: 17203008
[TBL] [Abstract][Full Text] [Related]
42. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.
Pakas I; Ioannidis JP; Malagari K; Skopouli FN; Moutsopoulos HM; Vlachoyiannopoulos PG
J Rheumatol; 2002 Feb; 29(2):298-304. PubMed ID: 11842824
[TBL] [Abstract][Full Text] [Related]
43. Simultaneous presence of neutrophil alveolitis and Ki-67 positivity of alveolar macrophages in dermato-/polymyositis and systemic sclerosis.
Kumánovics G; Magyarlaki T; Komócsi A; Szekeres G; Czirják L
Rheumatol Int; 2003 Jan; 23(1):6-10. PubMed ID: 12548435
[TBL] [Abstract][Full Text] [Related]
44. BALF-derived fibroblasts differ from biopsy-derived fibroblasts in systemic sclerosis.
Scheja A; Larsen K; Todorova L; Tufvesson E; Wildt M; Akesson A; Hansson L; Ellis S; Westergren Thorsson G
Eur Respir J; 2007 Mar; 29(3):446-52. PubMed ID: 17107986
[TBL] [Abstract][Full Text] [Related]
45. Induced sputum in systemic sclerosis interstitial lung disease: comparison to healthy controls and bronchoalveolar lavage.
Damjanov N; Ostojic P; Kaloudi O; Alari S; Guiducci S; Stanflin N; Nestorovic B; Knezevic J; Camiciottoli G; Porta F; Pistolesi M; Ibba-Manneschi L; Conforti ML; Candelieri A; Matucci Cerinic M
Respiration; 2009; 78(1):56-62. PubMed ID: 18931474
[TBL] [Abstract][Full Text] [Related]
46. Pharmacologic suppression of the neutrophil component of the alveolitis in idiopathic pulmonary fibrosis.
O'Donnell K; Keogh B; Cantin A; Crystal RG
Am Rev Respir Dis; 1987 Aug; 136(2):288-92. PubMed ID: 3619187
[TBL] [Abstract][Full Text] [Related]
47. Mechanisms of colchicine effect in the treatment of asbestosis and idiopathic pulmonary fibrosis.
Addrizzo-Harris DJ; Harkin TJ; Tchou-Wong KM; McGuinness G; Goldring R; Cheng D; Rom DW
Lung; 2002; 180(2):61-72. PubMed ID: 12172901
[TBL] [Abstract][Full Text] [Related]
48. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis.
Hesselstrand R; Wildt M; Bozovic G; Andersson-Sjöland A; Andréasson K; Scheja A; Westergren-Thorsson G; Bjermer L; Wuttge DM
Respir Med; 2013 Jul; 107(7):1079-86. PubMed ID: 23660398
[TBL] [Abstract][Full Text] [Related]
49. Pulmonary complications: one of the most challenging complications of systemic sclerosis.
Wells AU; Steen V; Valentini G
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii40-4. PubMed ID: 19487223
[TBL] [Abstract][Full Text] [Related]
50. Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases.
Vasakova M; Sterclova M; Kolesar L; Slavcev A; Pohunek P; Sulc J; Skibova J; Striz I
Scand J Immunol; 2009 Mar; 69(3):268-74. PubMed ID: 19281539
[TBL] [Abstract][Full Text] [Related]
51. [Potential predictors of therapeutic response in patients with cryptogenic fibrosing alveolitis].
Vysehradský R; Rozborilová E; Straková J; Polácek H; Hut'ka Z
Vnitr Lek; 2002 Mar; 48(3):185-91. PubMed ID: 11968578
[TBL] [Abstract][Full Text] [Related]
52. Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis.
Wells AU; Hansell DM; Haslam PL; Rubens MB; Cailes J; Black CM; du Bois RM
Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1474-82. PubMed ID: 9603126
[TBL] [Abstract][Full Text] [Related]
53. [Bronchoalveolar lavage in systemic scleroderma and systemic lupus erythematosus--differential cell values and enzyme cytochemistry].
Witt C; Eckert H; Brenke A; Renner H; Hiepe F
Z Erkr Atmungsorgane; 1991; 177(3):199-203. PubMed ID: 1808870
[TBL] [Abstract][Full Text] [Related]
54. Relationship Between Abnormalities on High-Resolution Computerized Tomography, Pulmonary Function, and Bronchoalveolar Lavage in Progressive Systemic Sclerosis.
Cakmak G; Selcuk Can T; Gundogdu S; Akman C; Ikitimur H; Musellim B; Ongen G
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Dec; 33(4):349-354. PubMed ID: 28079847
[TBL] [Abstract][Full Text] [Related]
55. [New knowledge on the diagnosis and prognosis of interstitial lung disease in scleroderma].
König G; Behr J; Luderschmidt C
Z Rheumatol; 1990; 49(5):279-83. PubMed ID: 2080684
[TBL] [Abstract][Full Text] [Related]
56. Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis.
van Oortegem K; Wallaert B; Marquette CH; Ramon P; Perez T; Lafitte JJ; Tonnel AB
Eur Respir J; 1994 Nov; 7(11):1950-7. PubMed ID: 7875264
[TBL] [Abstract][Full Text] [Related]
57. Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance.
Wells AU; Hansell DM; Rubens MB; Cullinan P; Haslam PL; Black CM; Du Bois RM
Am J Respir Crit Care Med; 1994 Aug; 150(2):462-8. PubMed ID: 8049830
[TBL] [Abstract][Full Text] [Related]
58. Evaluation and management of alveolitis and interstitial lung disease in scleroderma.
Latsi PI; Wells AU
Curr Opin Rheumatol; 2003 Nov; 15(6):748-55. PubMed ID: 14569205
[TBL] [Abstract][Full Text] [Related]
59. Subclinical pulmonary involvement assessed by bronchoalveolar lavage in patients with early undifferentiated connective tissue disease.
Kumánovics G; Zibotics H; Juhász E; Komócsi A; Czirják L
Clin Exp Rheumatol; 2001; 19(5):551-9. PubMed ID: 11579714
[TBL] [Abstract][Full Text] [Related]
60. [Study of high-resolution thoracic computerized tomography and bronchoalveolar lavage in 36 patients presenting with systemic disease and a normal thoracic radiography].
Dansin E; Wallaert B; Rémy-Jardin M; Perez T; Hatron PY; Rémy J; Tonnel AB
Rev Mal Respir; 1991; 8(6):551-8. PubMed ID: 1775714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
